|
Mar 29
|
Jim Cramer on Johnson & Johnson (NYSE:JNJ): Their Spinoff Was Ill-Advised
|
|
Mar 29
|
3 Relatively Safe Stocks to Buy Right Now
|
|
Mar 28
|
Sector Update: Health Care Stocks Softer Late Afternoon
|
|
Mar 28
|
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
|
|
Mar 28
|
J&J launches energy generator compatible with Ottava robot
|
|
Mar 28
|
2 Reasons to Like JNJ and 1 to Stay Skeptical
|
|
Mar 27
|
Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting
|
|
Mar 27
|
J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
|
|
Mar 27
|
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
|
|
Mar 27
|
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
|
|
Mar 27
|
J&J’s NSCLC combo projected to extend survival by one year over Tagrisso
|
|
Mar 27
|
2 Recession-Proof Dividend Stocks to Buy and Hold
|
|
Mar 26
|
Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off
|
|
Mar 26
|
Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate
|
|
Mar 26
|
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
|
|
Mar 26
|
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
|
|
Mar 26
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Mar 26
|
Johnson & Johnson MedTech introduces electrosurgical generator
|
|
Mar 26
|
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
|
|
Mar 24
|
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
|